List view / Grid view
25 January 2016 | By Victoria White
The Apollo Therapeutics Fund will support the translation of ground-breaking academic science into innovative new medicines for a broad range of diseases...
18 January 2016 | By Victoria White
The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies...
4 December 2015 | By Victoria White
The researchers made the discovery using mice modified to carry the same mutation as people born without Nav1.7. Their research revealed that people who lack Nav1.7 also produce higher than normal levels of natural opioid peptides...
14 October 2015 | By Victoria White
The three-year collaboration will focus on mechanistic approaches for the identification of genes or signalling pathways that modify neurodegenerative disease processes affecting neuronal health...
25 June 2015 | By Victoria White
Scientists from University College London have designed a chemical compound that has reduced the growth of pancreatic cancer tumours by 80% in treated mice...
Clearly what is needed is a synergistic collaboration bringing together the respective competence and expertise of academia and industry. All the major pharmaceutical companies have recognised this need and have introduced a range of different models for association with academia and small biotech or biopharma companies. Attempted solutions range from…
